Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (40)	7/3/2001 11:04:01 PM
From: Mark Bong	Read Replies (1) \| Respond to of 78

Probably a good entry point. It seems that labeling issues are the major FDA concern about Plenexis according to PRCS and AMGN in addition to some (resolvable) manufacturing issues outlined in a recent FDA letter. However, it is still too early to tell, and PRCS has not released the contents of the FDA letter to the public. If Plenexis is approved, you will probably get a nice bounce, but disapproval will probably result in more downside. I would not look for much before Q4, if then IMO. Good Luck.